ZA200307621B - Method of inhibiting adhesion formation. - Google Patents
Method of inhibiting adhesion formation. Download PDFInfo
- Publication number
- ZA200307621B ZA200307621B ZA200307621A ZA200307621A ZA200307621B ZA 200307621 B ZA200307621 B ZA 200307621B ZA 200307621 A ZA200307621 A ZA 200307621A ZA 200307621 A ZA200307621 A ZA 200307621A ZA 200307621 B ZA200307621 B ZA 200307621B
- Authority
- ZA
- South Africa
- Prior art keywords
- galkyl
- het
- sow
- compound
- alkyl
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title claims description 15
- 238000000034 method Methods 0.000 title description 16
- 230000002401 inhibitory effect Effects 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims description 15
- -1 -OR!1 Chemical group 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000001475 halogen functional group Chemical group 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 208000028257 Joubert syndrome with oculorenal defect Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 description 15
- 229940125904 compound 1 Drugs 0.000 description 14
- 238000001356 surgical procedure Methods 0.000 description 14
- 102100022337 Integrin alpha-V Human genes 0.000 description 13
- 108010048673 Vitronectin Receptors Proteins 0.000 description 13
- 239000002464 receptor antagonist Substances 0.000 description 10
- 229940044551 receptor antagonist Drugs 0.000 description 10
- 238000011887 Necropsy Methods 0.000 description 9
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000013401 experimental design Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 101100439664 Arabidopsis thaliana CHR8 gene Proteins 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 206010060932 Postoperative adhesion Diseases 0.000 description 2
- 208000031737 Tissue Adhesions Diseases 0.000 description 2
- 206010061401 Uterine injury Diseases 0.000 description 2
- 102000019997 adhesion receptor Human genes 0.000 description 2
- 108010013985 adhesion receptor Proteins 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- SNAKUPLQASYKTC-AWEZNQCLSA-N (3S)-3-[[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxymethyl]-N-phenylpiperidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC[C@@H]1CN(CCC1)C(=O)NC1=CC=CC=C1 SNAKUPLQASYKTC-AWEZNQCLSA-N 0.000 description 1
- BGYNBQAHKJEEHJ-QFIPXVFZSA-N 2-[(6s)-2-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-6,11-dihydro-5h-dibenzo[3,2-[7]annulen-6-yl]acetic acid Chemical compound C1=C2CC3=CC=CC=C3[C@H](CC(=O)O)CC2=CC=C1OCCC1=CC=C(CCCN2)C2=N1 BGYNBQAHKJEEHJ-QFIPXVFZSA-N 0.000 description 1
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
- LIDBMZYKSAXTQG-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-sulfamoylethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCS(N)(=O)=O)C=CC=1 LIDBMZYKSAXTQG-UHFFFAOYSA-N 0.000 description 1
- FJPUKTJEFOXMJX-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[1-(hydroxymethyl)cyclopropyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC2(CC2)CO)C=CC=1 FJPUKTJEFOXMJX-UHFFFAOYSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102100022631 Glutamate receptor ionotropic, NMDA 2C Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000032984 Intraoperative Complications Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010034238 Pelvic adhesions Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- KDSYNTPPPISIJB-UHFFFAOYSA-N [3-[[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxymethyl]phenyl]-(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone Chemical compound NCc1cc(OCc2cccc(c2)C(=O)N2CC(O)C(F)C2)nc(c1)C(F)(F)F KDSYNTPPPISIJB-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 210000005119 human aortic smooth muscle cell Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- JILPJDVXYVTZDQ-UHFFFAOYSA-N lithium methoxide Chemical compound [Li+].[O-]C JILPJDVXYVTZDQ-UHFFFAOYSA-N 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 108091008646 testicular receptors Proteins 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28269301P | 2001-04-10 | 2001-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200307621B true ZA200307621B (en) | 2004-04-21 |
Family
ID=23082703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200307621A ZA200307621B (en) | 2001-04-10 | 2003-09-30 | Method of inhibiting adhesion formation. |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP1385504B1 (es) |
| JP (1) | JP4394882B2 (es) |
| KR (1) | KR20030087069A (es) |
| CN (1) | CN1248692C (es) |
| AP (1) | AP2003002894A0 (es) |
| AT (1) | ATE417612T1 (es) |
| AU (1) | AU2002305164B2 (es) |
| BG (1) | BG108217A (es) |
| BR (1) | BR0208789A (es) |
| CA (1) | CA2443734A1 (es) |
| CZ (1) | CZ20032767A3 (es) |
| DE (1) | DE60230404D1 (es) |
| EA (1) | EA006202B1 (es) |
| EC (1) | ECSP034799A (es) |
| ES (1) | ES2319877T3 (es) |
| HU (1) | HUP0303725A3 (es) |
| IL (1) | IL158272A0 (es) |
| MA (1) | MA26159A1 (es) |
| MX (1) | MXPA03009344A (es) |
| NO (1) | NO20034513L (es) |
| NZ (1) | NZ528577A (es) |
| OA (1) | OA12505A (es) |
| PL (1) | PL364526A1 (es) |
| UA (1) | UA75395C2 (es) |
| WO (1) | WO2002083125A1 (es) |
| ZA (1) | ZA200307621B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200635902A (en) * | 2004-12-21 | 2006-10-16 | Smithkline Beecham Corp | Methods and formulations |
| RU2744540C1 (ru) * | 2020-02-18 | 2021-03-11 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ профилактики спаечного процесса при операциях на брюшной полости в условиях паренхиматозного кровотечения в эксперименте |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA60311C2 (uk) * | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція |
-
2002
- 2002-04-10 AU AU2002305164A patent/AU2002305164B2/en not_active Ceased
- 2002-04-10 BR BR0208789-8A patent/BR0208789A/pt not_active IP Right Cessation
- 2002-04-10 EP EP02733968A patent/EP1385504B1/en not_active Expired - Lifetime
- 2002-04-10 IL IL15827202A patent/IL158272A0/xx unknown
- 2002-04-10 AT AT02733968T patent/ATE417612T1/de not_active IP Right Cessation
- 2002-04-10 JP JP2002580929A patent/JP4394882B2/ja not_active Expired - Fee Related
- 2002-04-10 OA OA1200300271A patent/OA12505A/en unknown
- 2002-04-10 PL PL02364526A patent/PL364526A1/xx not_active Application Discontinuation
- 2002-04-10 EA EA200301109A patent/EA006202B1/ru not_active IP Right Cessation
- 2002-04-10 MX MXPA03009344A patent/MXPA03009344A/es active IP Right Grant
- 2002-04-10 AP APAP/P/2003/002894A patent/AP2003002894A0/en unknown
- 2002-04-10 NZ NZ528577A patent/NZ528577A/en unknown
- 2002-04-10 ES ES02733968T patent/ES2319877T3/es not_active Expired - Lifetime
- 2002-04-10 WO PCT/US2002/011285 patent/WO2002083125A1/en active IP Right Grant
- 2002-04-10 CN CNB028097874A patent/CN1248692C/zh not_active Expired - Fee Related
- 2002-04-10 DE DE60230404T patent/DE60230404D1/de not_active Expired - Lifetime
- 2002-04-10 KR KR10-2003-7013214A patent/KR20030087069A/ko active IP Right Grant
- 2002-04-10 HU HU0303725A patent/HUP0303725A3/hu unknown
- 2002-04-10 CZ CZ20032767A patent/CZ20032767A3/cs unknown
- 2002-04-10 CA CA002443734A patent/CA2443734A1/en not_active Abandoned
- 2002-10-04 UA UA2003109182A patent/UA75395C2/uk unknown
-
2003
- 2003-09-30 ZA ZA200307621A patent/ZA200307621B/en unknown
- 2003-10-01 BG BG108217A patent/BG108217A/bg unknown
- 2003-10-06 MA MA27339A patent/MA26159A1/fr unknown
- 2003-10-08 NO NO20034513A patent/NO20034513L/no not_active Application Discontinuation
- 2003-10-09 EC EC2003004799A patent/ECSP034799A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0303725A3 (en) | 2009-08-28 |
| OA12505A (en) | 2006-05-29 |
| ES2319877T3 (es) | 2009-05-14 |
| EP1385504A1 (en) | 2004-02-04 |
| PL364526A1 (en) | 2004-12-13 |
| ATE417612T1 (de) | 2009-01-15 |
| EA200301109A1 (ru) | 2004-02-26 |
| IL158272A0 (en) | 2004-05-12 |
| JP4394882B2 (ja) | 2010-01-06 |
| AP2003002894A0 (en) | 2003-12-31 |
| NO20034513D0 (no) | 2003-10-08 |
| MA26159A1 (fr) | 2004-07-01 |
| KR20030087069A (ko) | 2003-11-12 |
| JP2004525959A (ja) | 2004-08-26 |
| EP1385504B1 (en) | 2008-12-17 |
| HUP0303725A2 (hu) | 2004-03-01 |
| CN1248692C (zh) | 2006-04-05 |
| BR0208789A (pt) | 2004-03-09 |
| WO2002083125A1 (en) | 2002-10-24 |
| MXPA03009344A (es) | 2004-02-12 |
| CN1509170A (zh) | 2004-06-30 |
| CZ20032767A3 (cs) | 2004-12-15 |
| CA2443734A1 (en) | 2002-10-24 |
| BG108217A (bg) | 2004-12-30 |
| NO20034513L (no) | 2003-12-04 |
| DE60230404D1 (es) | 2009-01-29 |
| UA75395C2 (en) | 2006-04-17 |
| EP1385504A4 (en) | 2007-03-14 |
| AU2002305164B2 (en) | 2005-07-28 |
| EA006202B1 (ru) | 2005-10-27 |
| ECSP034799A (es) | 2004-01-28 |
| NZ528577A (en) | 2005-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220152052A1 (en) | Methods and compositions for treating various disorders | |
| CN100377742C (zh) | 包含低分子量凝血酶抑制剂及其药物前体的药用制剂 | |
| US6472379B1 (en) | Angiogenesis inhibition | |
| JP2003519183A (ja) | 心臓および動脈の石灰化を抑制する低用量ビスホスホネートの使用 | |
| US8648100B2 (en) | Roflumilast for the treatment of pulmonary hypertension | |
| ZA200105275B (en) | New use of melagatran. | |
| ZA200307621B (en) | Method of inhibiting adhesion formation. | |
| AU2002305164A1 (en) | Method of inhibiting adhesion formation | |
| US20040142918A1 (en) | Method of inhibiting adhesion formation | |
| TW200306811A (en) | Medicinal compositions for inhibiting tryptase | |
| Qian et al. | Effects of intraperitoneal (IP) different doses of ketamine on cognitive function in aged rats: 9AP6-8 | |
| CN101219204A (zh) | 包含低分子量凝血酶抑制剂及其药物前体的药用制剂 |